Ludotadipep is under clinical development by FutureChem and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ludotadipep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ludotadipep is under development for the treatment of metastatic castration-resistant prostate cancer. It is administered through intravenous route. It is a Lu-177 radiolabeled compound. It acts by targeting PSMA.
FutureChem is engaged in the manufacture of medicaments. The company offers radiopharmaceuticals for the diagnosis of cancer, lung cancer, Parkinson’s disease and Alzheimer’s disease. The company is also involved in chemical business which produces and develops PET and SPECT precursors, linkers, fluorescence probe, ionic liquid, amino acids and reagent for peptide. In addition, it also offers automation modules such as sCUBE RXN, sCUBE P&F, sCUBE A sCUBE M, and disposable goods includes Cassette, Reagent Kit and Radio-Cap. FutureChem is headquartered in Seongdong-gu, Seoul, South Korea.
For a complete picture of Ludotadipep’s drug-specific PTSR and LoA scores, buy the report here.